Oncology Billing Guide 2026: Chemotherapy, Infusion Therapy, and Drug Administration Coding

Published June 10, 2026 · 14 min read · By RCMAXIS Revenue Cycle Team

Oncology billing is among the most complex — and highest-stakes — billing environments in medicine. A single chemotherapy infusion visit can generate $3,000–$18,000 in billable services, and a single coding error on infusion sequencing, drug administration hierarchy, or concurrent therapy rules can cost that entire claim. The average oncology practice operates at a 14.3% denial rate, the highest of any specialty, driven primarily by infusion hierarchy errors, prior authorization failures for high-cost drugs, and documentation shortfalls on medical oncology E/M visits.

This guide covers the five pillars of oncology revenue: chemotherapy administration coding, infusion therapy hierarchy rules, oncology E/M billing, drug administration (non-chemo), and prior authorization management for biologics and targeted therapies.

1. Chemotherapy Administration Codes

Chemotherapy administration codes differ from standard infusion codes and carry higher reimbursement rates. The correct code depends on the route of administration (IV push vs. infusion), the duration, and whether it is the primary service of the visit or an add-on concurrent with another service.

Infusion Hierarchy Rule — the Most Misunderstood Rule in Oncology Billing

When multiple infusion services are provided in a single visit, the infusion hierarchy determines which code is billed as the "primary" service and which are add-ons. This is not the order in which drugs were given — it is a hierarchy of service type:

1. Chemotherapy infusion (96413) — always primary if performed, regardless of whether it started first
2. Chemotherapy IV push (96409) — primary if no chemo infusion occurred
3. Therapeutic/diagnostic infusion (96365) — primary only if no chemo administered
4. Hydration (96360) — never primary when any other infusion is present; always concurrent add-on

Common error: billing hydration (96360) as the primary service when the patient also received chemotherapy. Correct: 96413 is primary, hydration is concurrent (96361 add-on). Billing them in the wrong hierarchy order causes systematic denials.

2. Non-Chemo Infusion and Therapeutic Drug Administration

Most oncology visits include non-chemotherapy infusions — antiemetics, growth factors, immunotherapy agents, and supportive care drugs. These are billed using the therapeutic infusion codes (96365–96368), not the chemotherapy codes, and follow the same hierarchy logic.

Immunotherapy and Checkpoint Inhibitors

Checkpoint inhibitors (pembrolizumab/Keytruda, nivolumab/Opdivo, atezolizumab/Tecentriq) are non-chemotherapy agents billed under 96365 series, not 96413 series. This is one of the most common oncology coding errors:

• Immunotherapy agents are NOT chemotherapy for billing purposes — use 96365 (therapeutic infusion), not 96413 (chemo infusion)
• However, when immunotherapy is given on the same day as chemotherapy, 96413 remains the primary code (hierarchy), and the immunotherapy becomes a sequential (96367) or concurrent (96368) infusion
• Prior authorization is required for virtually every checkpoint inhibitor and must specify the diagnosis, line of therapy, and biomarker status (PD-L1, TMB, MSI) for approval

3. Oncology E/M Visits: New Patient vs. Established

Medical oncology E/M visits are among the most undervalued in oncology practice. The complexity of cancer care — multiple co-morbidities, treatment toxicity management, prognostic discussions — routinely justifies 99214 and 99215 coding, yet most practices default to 99213 out of misplaced caution.

Scoring Oncology Visits Under 2021 AMA Guidelines

The 2021 E/M guidelines determine level by either Medical Decision Making (MDM) or Total Time. Oncology visits qualify for high-level coding on both pathways:

• 99215 — High complexity MDM: Patient with cancer on active treatment, reviewing labs, managing toxicities, coordinating with radiation/surgery, discussing prognosis — this is high complexity MDM. Document: number of diagnoses/management options addressed, amount/complexity of data reviewed (lab results, imaging, pathology), risk of complications/morbidity/mortality
• 99215 — Time: 40–54 minutes total time including pre/post-visit documentation. Most new oncology consultations and complex follow-ups exceed this threshold
• 99214 — Moderate complexity MDM: Established patient, stable on maintenance therapy, labs reviewed, no toxicity — moderate complexity when 2+ chronic conditions addressed

Same-Day E/M with Infusion (Modifier 25)

An oncology E/M visit on the same day as chemotherapy infusion requires modifier 25 on the E/M code. Without modifier 25, most payers bundle the E/M into the infusion service and deny it. Key documentation requirements:

• The E/M must be a separate, separately documented service — not just a pre-infusion check with vital signs
• Document: history, clinical assessment, medication review, toxicity evaluation, treatment plan decision — this constitutes a billable E/M independent of the infusion
• Medicare and most commercial payers allow same-day E/M with infusion when modifier 25 is applied and documentation supports a separate service

4. Drug Billing: J-Codes and Buy-and-Bill

Chemotherapy and infusion drugs are billed using HCPCS Level II J-codes. The buy-and-bill model — where the practice purchases drugs wholesale and bills payers at the allowed amount — represents a significant component of oncology practice revenue. Accurate drug billing requires precise dosing documentation and correct NDC (National Drug Code) reporting.

NDC Reporting Requirements

Medicare and many commercial payers require NDC (National Drug Code) reporting on all drug claims. Missing or incorrect NDC is a top claim denial driver in oncology:

• Report NDC in the format: qualifier (N4) + 11-digit NDC + unit qualifier (UN = units, ML = milliliters, GR = grams) + quantity
• Use the NDC from the vial actually administered — not a generic NDC or a reference NDC
• When multiple vials of the same drug are used in one session, report the NDC of each lot if different, or one NDC with combined quantity
• Drug wastage: when a partial vial is used and the remainder is discarded, bill the total dose administered (not the full vial) unless your payer contract allows wastage billing — verify per contract

5. Prior Authorization for Oncology Drugs

Prior authorization is a major operational bottleneck in oncology. Most high-cost oncology drugs — targeted therapies, immunotherapy, biosimilars — require authorization before administration, and treatment delays caused by auth failures are a patient care crisis as well as a revenue issue.

Oncology PA Best Practices

• Submit PA before first dose: Even for urgent cases, initiate authorization at the time of treatment planning — average PA turnaround for oncology drugs is 3–7 business days for standard review, 24–72 hours for expedited
• Include biomarker data: Most immunotherapy PAs require PD-L1 expression, TMB, MSI status, or EGFR/ALK mutation documentation. Missing biomarker data is the #1 reason for oncology PA initial denial
• Line of therapy documentation: Payers require documentation of prior treatment lines. If pembrolizumab is being used as first-line, document that clearly — if second-line, document what first-line therapy failed and when
• NCCN guideline citation: Reference the specific NCCN category (1, 2A, 2B) for the requested regimen. Category 1 recommendations have the highest approval rates; Category 2B requires additional medical necessity justification
• Peer-to-peer appeals: Oncology PA denials have the highest overturn rate through peer-to-peer review (62–78% overturn) — always pursue P2P before sending written appeals

6. Radiation Oncology Billing Overview

Medical oncology and radiation oncology billing are managed separately. Radiation oncology practices bill under a distinct code set involving treatment planning, simulation, and delivery codes. Key codes for context:

• 77261–77263: Radiation treatment planning — simple, intermediate, complex. Documentation must describe fields, beam configuration, and plan complexity
• 77300: Basic dosimetry calculation — billed per treatment plan modification
• 77385–77386: Intensity modulated radiation therapy (IMRT) delivery — simple vs. complex. IMRT requires prior auth from most payers and documentation of why 3D conformal radiation is insufficient
• 77427: Radiation treatment management — weekly physician treatment management, per 5 fractions. Bill once per 5 fractions completed
• G6001–G6017: IMRT planning and delivery HCPCS codes — used by some payers in place of CPT codes for radiation services

Oncology billing demands coding expertise that most generalist billing companies cannot provide. RCMAXIS fields dedicated oncology revenue cycle specialists who understand infusion hierarchy, drug J-code precision, and the PA workflow for high-cost biologics. Start with a free revenue assessment to identify where your oncology practice is losing revenue.